The BESTCILIA trial presented strong evidence that a low dose of azithromycin over a period of 6 months can help prevent exacerbation in primary ciliary dyskinesia (PCD) and reduce pathogenic bacteria in the sputum.
PCD is a rare condition. The signs of this congenital disease start in neonates or young children, and it progresses throughout adulthood. Symptoms include chronic rhinosinusitis, recurrent otitis media, conductive hearing impairment, chronic productive cough, as well as infection and inflammation of the lower respiratory tract . Currently, data on PCD is still scarce.
Dr Helene Kobbernagel (Rigshospitalet Copenhagen, Denmark) presented the results of the randomised controlled, European, multicentre BESTCILIA trial . The trial investigated efficacy and safety of azithromycin as a maintenance therapy to prevent respiratory exacerbations of PCD. Participants (n=90), aged 7-50 years, were randomised to receive either placebo (n=41) or...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Fever During Immunotherapy for NSCLC Associated with Shorter PFS Next Article
Letter from the Editor and Biography »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.